CoChat
Sign Up
Cited by 261Diabetes Treatment and ManagementGastrointestinal motility and disordersDiabetes Management and Research

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Linnebjerg, Helle, Park, Soomin, Kothare, Prajakti A., Trautmann, Michael E., Mace, Kenneth, Fineman, Mark, Wilding, Ian, Nauck, Michael, Horowitz, Michael·2008·Regulatory Peptides
DOI 10.1016/j.regpep.2008.07.003
Open this paper in CoChat — free account

Abstract

Objectives To evaluate the effect of exenatide on gastric emptying (GE) in type 2 diabetes using scintigraphy. Methods Seventeen subjects with type 2 diabetes participated in a randomized, single-blind, 3-period, crossover study. In each 5-day period, 5 or 10 microg exenatide or placebo was administered subcutaneously BID. Oral antidiabetic treatments were continued. The presence of cardiac autonomic neuropathy was assessed during screening. On day 5, after the morning dose, subjects consumed a 450-kcal breakfast containing (99m)Tc-labeled eggs and (111)In-labeled water, and GE was measured by scintigraphy. Plasma glucose and insulin, perceptions of appetite, and plasma exenatide were also quantified. Results Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)]. GE was not different between subjects with cardiac autonomic neuropathy (n=7), compared with those without (n=10) (P>/=0.68). Exenatide reduced postprandial glucose (area under the curve [AUC((0-6 h))]) by 69-76% and peak insulin (C(max)) by 84-86% compared with placebo. There was an inverse relationship between the postprandial rise in glucose (AUC((0-3 h))) and GE (solid T(50), r=-0.49, P<0.001). Conclusions Exenatide slows GE substantially in type 2 diabetes, which could be an important mechanism contributing to the beneficial effect of exenatide on postprandial glycemia.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.regpep.2008.07.003

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 40 references

1 of the 40 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Nauck, 1997, Rapid tachyphylaxis for the deceleration of gastric emptying by exogenous GLP-1, Gastroenterol, 112, A797

Cited by

Sorted by citations

Items 201–261 of 261

Related

See all

Metadata

Authors
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M.
Affiliations
  • Eli Lilly (United States) (US)
  • Diabeteszentrum Bad Lauterberg (DE)
  • Royal Adelaide Hospital (AU)
Corresponding author
Linnebjerg, Helle
ORCID
Venue
Regulatory Peptides
Publisher
Elsevier BV
Published
2008-11
Volume
151
Issue
1-3
Pages
123-129
ISSN
0167-0115 (ISSN-L)
DOI
10.1016/j.regpep.2008.07.003
OpenAlex
W1984845045
Cited by
261
References
40
Citations by year
2026: 6 · 2025: 14 · 2024: 17 · 2023: 10 · 2022: 11 · 2021: 13 · 2020: 13 · 2019: 19 · 2018: 7 · 2017: 9 · 2016: 12 · 2015: 23 · 2014: 18 · 2013: 24 · 2012: 18
FWCI
11.37
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Regulatory Peptides (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Amylin Pharmaceuticals
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
exenatide, gastric emptying, type 2 diabetes, postprandial blood glucose, GLP-1 receptor agonists, cardiac autonomic neuropathy, insulin response, appetite, meal timing, GLP-1 receptor antagonists
MeSH terms
Exenatide, Aged, Appetite, Blood Glucose, Diabetes Mellitus, Type 2, Drug Tolerance, Female, Gastric Emptying, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Safety, Venoms, Single-Blind Method, Cross-Over Studies, Postprandial Period

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review